The seroepidemiology of measles in Western Europe

Epidemiology and Infection

Volumn 126, Issue 2, 2001, Pages 249-259

  De Melker, H ^a   Pebody, R G ^b   Edmunds, W J ^b   Levy Bruhl D ^c   Valle, M ^d   Rota, M C ^e   Salmaso, S ^e   Van Den Hof, S ^a   Berbers, G ^a   Saliou, P ^f   Conyn Van Spaendonck, M ^a   Crovari, P ^j   Davidkin, I ^d   Gabutti, G ^j   Hesketh, L ^g   Morgan Capner, P ^g   Plesner, A M ^h   Raux, M ^f   Tischer, A ⁱ   Miller, E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c Reseau Natl de S Publique   (France)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f SANOFI PASTEUR   (France)

^g Public Health Laboratory   (United Kingdom)

^h STATENS SERUM INSTITUT   (Denmark)

ⁱ ROBERT KOCH INSTITUTE   (Germany)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CONTROLLED STUDY; EPIDEMIC; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEASLES; POLITICS; SEROEPIDEMIOLOGY; SEROLOGY; VIRUS TRANSMISSION; WESTERN EUROPE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; EUROPE; HUMANS; INCIDENCE; INFANT; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; POPULATION SURVEILLANCE; QUESTIONNAIRES; SEROEPIDEMIOLOGIC STUDIES;

EID: 0035005750     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268801005234     Document Type: Article

References (25)

1. Mandell R, Douglas G, Bennett JE. Measles virus (Rubeola). In: Principles and practice of infectious diseases, 3rd edn. Churchill Livingstone, New York, 1990: 1280-6.
2. Shepard D. Economic analysis of investment priorities for measles control. J Infect Dis 1994; 170 (Suppl 1): S56-62.
3. Anonymous. Progress toward global measles control and regional elimination, 1990-1997. MMWR 1998; 47: 1049-54.
4. World Health Organization. Strategic plan for the elimination of measles in the European Region. CMDS 01 01 06/10 March 3, 1997. Copenhagen, Denmark: WHO Regional Office for Europe, Copenhagen, Denmark.
5. Lévy-Bruhl D, Pebody R, Veldhuijzen I, Valenciano M, Osborne K. European Sero-Epidemiological Network: Descriptive analysis of vaccination programmes for measles, mumps and rubella. Eurosurveillance 1998; 3: 115-9.
6. World Health Organisation Regional Office for Europe. Thirteenth Meeting of the European Advisory Group on the Expanded Programme on Immunisation (EAG/EPI). Paris, France, 10-12 March 1997.
7. Osborne K, Weinberg J, Miller E. The European Sero-Epidemiological Network. Eurosurveillance 1997; 2: 29-31.
8. Edmunds WJ, Pebody RG, Aggerback H, Baron S, Berbers G, Conynm M, Hallander H, Lander R, Maple PAC, de Melker H, Olin P, Fievret-Groyne F, Rota C, Salmaso S, Tischer A, von-Hunolstein C, Miller E. The sero-epidemiology of diphtheria in Western Europe. Epidemiol Infect: In press.
9. Andrews N, Pebody RG, Berbers G, Blondeau C, Crovari P, Davidkin I, Farrington P, Fievet-Groyne F, Gabutti G, Gerike E, Giordano C, Hesketh L, Marzec T, Morgan Capner P, Osborne K, Pleisner AM, Raux M, Tischer A, Ruden U, Valle M, Miller E. The European Sero-Epidemiology Network: standardising the enzyme immunoassay results for measles, mumps and rubella. Epidemiol Infect: In press.
10. Gay N. Analysis of seroprevalence data for measles, mumps and rubella in six European countries: estimation of MMR vaccine coverage and prevalence of past infection. Epidemiol Infect: In press.
11. Vaccine preventable diseases of childhood, England and Wales. CDR 2000; 10: 2.
12. Salmaso S, Rota MC, Ciofi degli Atti ML, Tozzi AE, Kreidl P, and the ICONA Study Group. Simultaneous EPI cluster surveys to estimate regional infant immunisation coverage in Italy. Bull WHO 1999; 77: 843-51.
13. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination programme. New Engl J Med 1994; 331: 1397-402.
14. Peltola H, Davidkin I, Valle M, Paunio M, Hovi T, Hienonen OP, Leinikki P. No measles in Finland. Lancet 1997; 350: 1364-5.
15. Hof S van den, Conyn-van Spaendonck MAE, Melker HE de, Geubbels ELPE, Suijkerbuijk AWM, Talsma E, Plantinga AD, Rümke HC. The effects of vaccination, the incidence of the target diseases. National Institute of Public Health and the Environment Report No. 213676008, Bilthoven, 1998.
16. Anonymous. Measles outbreak - Netherlands. April 1999 January 2000. MMWR 2000; 49: 299-303.
17. Gay N, Ramsay M, Cohen B, Hesketh L, Morgan-Capner P, Brown D, Miller E. The epidemiology of measles in UK since the 1994 vaccination campaign. CDR Rev 1997; 7: R17-R21.
18. Gerike G, Rasch A, Tischer S. Santibanez Measles in Germany. Eurosurveillance 1997; 2: 88-90
19. Santoro R, Ruggeri FM, Battaglia M, Rapicetta M, Grandolfo ME, Annesi I, Cortellessa CM. Measles epidemiology in Italy. Int J Epidemiol 1984; 13: 201-9.
20. Measles official notifications data 1980 96 (computer file). Italian National Institute of Statistics (ISTAT) database. Official measles notification data 1960-96.
21. Miller DL. Frequency of complications of measles, 1963. BMJ 1964; II: 75-8.
22. Duclos P, Tepper LCML, Weber J, Marusyk RG. Seroprevalence of measles-and rubella-specific antibodies among military recruits, Canada, 1991. Rev Can Sant Publ 1994; 85: 278-81.
23. Cutts FT, Markowitz LE. Successes and failures in measles control. J Infect Dis 1994; 170 Suppl 1: S32-41.
24. Gustafson TL, Lievens AW, Brunell PA, Moellenberg RG, Christopher BS, Buttery MG, Sehulster LM. Measles outbreak in a fully immunized secondary-school population. New Engl J Med 1987; 316: 771-4.
25. Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 1998; 16: 2052-7.